Why did revenue grow so much faster than adjusted income?

Most of the revenue growth came from Evernorth's pharmacy benefit business, which carries low margins. Pharmacy Benefit Services revenue rose 41%, while its pre-tax adjusted income rose only 3%, and the Evernorth pre-tax margin fell to 3.3% from 4.0%. Management attributed this to planned investments supporting client growth and the mix shift toward lower-margin pharmacy revenue.

What is happening with customer counts?

Total customer relationships increased 13% since December 31, 2023 to 186.2 million, driven by pharmacy customers, which rose to 122.5 million. Total medical customers declined to 19.0 million, mainly because of targeted pricing actions in Individual and Family Plans. Behavioral Care customers also fell due to non-renewal of supplemental contracts that management described as insignificant to results.

How is Cigna returning capital to shareholders?

Through July 31, 2024, Cigna bought back 14.7 million shares for about $5.0 billion, including 9.3 million shares for $3.2 billion under Accelerated Share Repurchase agreements. The 2024 outlook includes expected future repurchases. Weighted average shares are guided to 282 million to 286 million for the year, and buybacks drove the reduction from 296.9 million in Q2 2023.

Why did the Corporate and Other segment loss widen?

The adjusted pre-tax loss in Corporate and Other Operations grew to $451 million from $394 million, primarily reflecting higher interest expense. Investors should watch this line as debt levels and rates affect the company's cost of capital.

CI 8-K: Earnings & Results

Q: Is the medical cost trend a concern for Cigna Healthcare?

The medical care ratio rose to 82.3% from 81.2% a year earlier. About 40 basis points of that increase came from roughly $50 million in unfavorable prior-year Medicare Advantage risk adjustments, and business mix also contributed. Full-year guidance of 81.7% to 82.5% suggests management expects the ratio to stay elevated relative to 2023.

01—Abstract

Summary

Summary of the 8-K filed August 1, 2024. Cited figures are marked; the original filing is the authoritative source.

The Cigna Group (CI) reported strong second quarter 2024 results on August 1, 2024, with total revenues up 25% year over year to $60.5 billion^a, driven mainly by large client wins at Evernorth Health Services.

Shareholders' net income was $1.5 billion^b, or $5.45 per share, versus $4.92 a year earlier. Adjusted income from operations, the company's principal profitability measure, rose 5% to $1.9 billion, or $6.72 per share. Growth was broad-based, with Evernorth adjusted revenues up 30% and adjusted pre-tax income up 7%, while Cigna Healthcare adjusted pre-tax income rose 3% on modest 3% revenue growth.

The quality of the quarter is nuanced. Pharmacy Benefit Services revenue grew 41%, but its adjusted pre-tax income rose only 3%, and the consolidated adjusted pre-tax margin for Evernorth compressed to 3.3% from 4.0%, reflecting planned investments and a lower-margin revenue mix. Cigna Healthcare's medical care ratio rose to 82.3% from 81.2%, including about $50 million^c of unfavorable prior-year Medicare Advantage risk adjustment.

Corporate and Other losses widened to $451 million^d on higher interest expense. Management raised its 2024 adjusted income from operations outlook to at least $28.40 per share, with adjusted revenues of at least $235 billion. Capital deployment remained active.

Cigna repurchased 14.7 million shares for about $5.0 billion year to date through July 31, 2024, including $3.2 billion under Accelerated Share Repurchase agreements, and the debt-to-capitalization ratio improved to 43.6% from 44.3%. Total customer relationships rose 13% since year-end 2023 to 186.2 million, though total medical customers declined to 19.0 million on targeted pricing actions in Individual and Family Plans, and the full-year medical customer outlook is about 19.3 million. Investors should weigh the strong top-line growth and buybacks against thin Evernorth margins and medical cost pressure.

02—Key points

Key Highlights

Total revenues rose 25% year over year to $60.5 billion in Q2 2024, driven mainly by Evernorth client wins.
Adjusted income from operations was $1.9 billion, or $6.72 per share, up 5% from $6.13 a year earlier.
GAAP shareholders' net income was $1.5 billion, or $5.45 per share, compared with $4.92 in Q2 2023.
2024 outlook raised to adjusted income from operations of at least $8.065 billion, or at least $28.40 per share, with adjusted revenues of at least $235 billion.
Evernorth Pharmacy Benefit Services adjusted revenues grew 41%, but adjusted pre-tax income rose only 3%, and Evernorth's pre-tax margin fell to 3.3% from 4.0%.
Cigna Healthcare medical care ratio rose to 82.3% from 81.2%, including about $50 million of unfavorable prior-year Medicare Advantage risk adjustment.
Year-to-date share repurchases reached 14.7 million shares for about $5.0 billion through July 31, 2024; debt-to-capitalization improved to 43.6%.

03—Questions

Frequently Asked Questions

Why did revenue grow so much faster than adjusted income?
Most of the revenue growth came from Evernorth's pharmacy benefit business, which carries low margins. Pharmacy Benefit Services revenue rose 41%, while its pre-tax adjusted income rose only 3%, and the Evernorth pre-tax margin fell to 3.3% from 4.0%. Management attributed this to planned investments supporting client growth and the mix shift toward lower-margin pharmacy revenue.
Is the medical cost trend a concern for Cigna Healthcare?
The medical care ratio rose to 82.3% from 81.2% a year earlier. About 40 basis points of that increase came from roughly $50 million in unfavorable prior-year Medicare Advantage risk adjustments, and business mix also contributed. Full-year guidance of 81.7% to 82.5% suggests management expects the ratio to stay elevated relative to 2023.
What is happening with customer counts?
Total customer relationships increased 13% since December 31, 2023 to 186.2 million, driven by pharmacy customers, which rose to 122.5 million. Total medical customers declined to 19.0 million, mainly because of targeted pricing actions in Individual and Family Plans. Behavioral Care customers also fell due to non-renewal of supplemental contracts that management described as insignificant to results.
How is Cigna returning capital to shareholders?
Through July 31, 2024, Cigna bought back 14.7 million shares for about $5.0 billion, including 9.3 million shares for $3.2 billion under Accelerated Share Repurchase agreements. The 2024 outlook includes expected future repurchases. Weighted average shares are guided to 282 million to 286 million for the year, and buybacks drove the reduction from 296.9 million in Q2 2023.
Why did the Corporate and Other segment loss widen?
The adjusted pre-tax loss in Corporate and Other Operations grew to $451 million from $394 million, primarily reflecting higher interest expense. Investors should watch this line as debt levels and rates affect the company's cost of capital.

04—Continue

← View all 8-K filings